In adjusting to the long-term side-effects of the coronavirus pandemic, pharma companies will need to focus on change in three areas. Ben van der Schaaf and Aurelien Guichard report.
Ben van der Schaaf and Aurelien Guichard
Advertisement
Ben van der Schaaf is Partner and Aurelien Guichard is Manager and US Lead for Energy & Utilities, both at Arthur D. Little.
Articles by Ben van der Schaaf and Aurelien Guichard
Advertisement
Latest Updated Articles
Strategic Realignment for a Better FuturePublished: July 21st 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
2
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
3
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
4
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
5
